Acute leukemia of ambiguous lineage
Information
- Disease name
- Acute leukemia of ambiguous lineage
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02220985 | Active, not recruiting | Phase 2 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | February 3, 2015 | April 1, 2025 |
| NCT02828358 | Active, not recruiting | Phase 2 | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | April 1, 2017 | September 22, 2024 |
| NCT03012672 | Completed | Phase 2 | Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm | December 30, 2016 | February 26, 2021 |
| NCT01319864 | Completed | Phase 1 | POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients | March 2011 | June 28, 2016 |
| NCT01858740 | Completed | Phase 2 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | April 10, 2014 | July 30, 2023 |
| NCT02135874 | Completed | Phase 2 | Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia | October 27, 2014 | February 21, 2023 |
| NCT06355583 | Not yet recruiting | Phase 2 | Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial | April 15, 2024 | May 1, 2027 |
| NCT04440267 | Not yet recruiting | Phase 2 | Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage | June 20, 2020 | December 20, 2025 |
| NCT05521087 | Not yet recruiting | Phase 1 | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias | December 26, 2025 | January 29, 2030 |
| NCT06317662 | Not yet recruiting | Phase 2 | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | July 31, 2024 | December 21, 2027 |
| NCT04067336 | Recruiting | Phase 1/Phase 2 | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | September 12, 2019 | September 30, 2025 |
| NCT05292664 | Recruiting | Phase 1 | Venetoclax Basket Trial for High Risk Hematologic Malignancies | March 29, 2023 | April 2, 2027 |
| NCT06177067 | Recruiting | Phase 1 | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | April 19, 2024 | July 2026 |
| NCT05901974 | Recruiting | Phase 2 | Venetoclax Combined With Azactidine in the Treatment of ALAL | July 1, 2021 | July 1, 2025 |
| NCT06013423 | Recruiting | Phase 2 | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | July 6, 2024 | October 31, 2025 |
| NCT03779854 | Recruiting | Phase 2 | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | August 29, 2019 | December 31, 2025 |
| NCT04065399 | Recruiting | Phase 1/Phase 2 | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | November 5, 2019 | December 2024 |
| NCT01701323 | Terminated | Phase 1 | Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | December 10, 2012 | May 10, 2018 |